Chief editor, Rob Wright, discusses some forward-looking sessions from the annual CNS Summit, along with what to expect in Life Science Leader’s annual outlook issue.

We asked multiple biopharma CEOs everything from which executives or companies they pay close attention to in and outside of their industry, to questions about geopolitical issues, tech trends, and everything in between.

Rob Wright shares what makes the CNS Summit the best conference he has ever attended.

Liz Barrett shares some of the formative experiences that shaped her into the leader she has become, including one of the most recent challenges she is embracing at Novartis.

A tour of the Netherlands’ life sciences industry takes our chief editor back to the global headquarters of his former employer, Organon Pharmaceuticals.

What sets the Netherlands biopharma sector apart from the rest of the world? That’s what Chief Editor Rob Wright hoped to find out as he began his press tour of the country’s biopharma industry.

Our chief editor explains that the rationale for creating some of our most popular sections was to give readers the insights and perspectives of those who have “been there, experienced that.”

When Lou Schmukler joined Bristol-Myers Squibb (BMS) in 2011, it was analogous to jumping onto a moving train. The company’s biopharma transformation was barreling ahead at full steam. More change was coming, and the company’s manufacturing operations would need to move fast to keep up.

Rob Wright discusses China’s history of intellectual property (IP) theft, and wonders if the government-sponsored 10-year initiative, Made in China 2025 (MIC 2025), could exacerbate the problem.